Cheah Chan Yoon, Seymour John F
Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Curr Oncol Rep. 2015 Jun;17(6):25. doi: 10.1007/s11912-015-0450-4.
Secondary central nervous system (CNS) progression in patients with non-Hodgkin lymphoma (NHL) is associated with a particularly poor prognosis. In this review, we summarize and critically evaluate the current literature to guide the practicing clinician in estimating CNS relapse risk in order to select individual patients who may benefit from CNS prophylaxis, covering histologic subtype, anatomic location, and molecular and clinical factors. We summarize the data regarding different prophylaxis strategies used and provide our recommendation regarding who should receive it, what they should receive, and when it should be administered.
非霍奇金淋巴瘤（NHL）患者的中枢神经系统（CNS）继发性进展与特别差的预后相关。在本综述中，我们总结并批判性地评估当前文献，以指导临床医生评估CNS复发风险，从而选择可能从CNS预防中获益的个体患者，内容涵盖组织学亚型、解剖位置以及分子和临床因素。我们总结了有关所使用的不同预防策略的数据，并就谁应接受预防、应接受何种预防以及何时进行预防提供我们的建议。
